GlassScriptPhysician profile
Crystal G Roe
NPI 1861871857
$972.45
in general payments reported to CMS, 2019-2025
21 companies · $91.33 in 2025
The $91.33 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2021: $29.38 · 2022: $280 · 2023: $114 · 2024: $232 · 2025: $91.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $187.66 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $90.24 | 2019-2024 | Vraylar |
| Novo Nordisk INC | $78.86 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $74.38 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $63.59 | 2019-2024 | Farxiga |
| Pfizer INC. | $55.06 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.89 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.55 | 2024 | Xifaxan |
| Amgen INC. | $41.40 | 2019-2024 | Repatha, Otezla |
| Supernus Pharmaceuticals, INC. | $41.30 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $40.71 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.35 | 2019 | |
| Exact Sciences Corporation | $27.86 | 2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $25.56 | 2023 | Epclusa |
| Amarin Pharma, INC. | $24.36 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $24.34 | 2019 | |
| Evofem Biosciences, INC. | $19.29 | 2022 | |
| Abbott Laboratories | $17.16 | 2022 | |
| Merck Sharp & Dohme LLC | $15.38 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $10.79 | 2019 | |
| Organon LLC | $5.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.